Enter multiple symbols separated by commas



  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • Moderna Therapeutics No. 1 on Disruptor 50: Here's why

    Moderna Therapeutics' CEO Stephane Bancel discusses the company's discovery of utilizing messenger RNA, which helps to direct the body's own cells to build proteins and fight rare diseases.

  • COPENHAGEN, May 8- Investors have high hopes for Novozymes and the enzymes it makes to improve chemical processes in a variety of industries, but analysts warn of pitfalls in a growth strategy reliant on a biofuel sector still in its infancy and unproven farming biotechnology. Having built on mother company Novo's work in the 1940 s to produce biological...

  • CHICAGO, May 7- Could the one percent soon get to live twice as long as the rest of us- maybe even forever? Immortality may not be in the cards just yet, but exponential breakthroughs in technology and medicine will make possible lifespans of 150 years or more, according to Ken Dychtwald. American men live an average of two years longer than they did in 2000, and women...

  • Is the market leadership changing?   Thursday, 30 Apr 2015 | 5:00 PM ET
    Is the market leadership changing?

    Are transport stocks and biotechs giving up their market leadership? Andrew Burkly of Oppenheimer and Rich Ross of Evercore ISI discuss with Brian Sullivan.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • Promising cancer drugs   Friday, 17 Apr 2015 | 4:42 PM ET
    Promising cancer drugs

    The fight against Alzheimer's disease and cancer take center stage at conferences this weekend. Details, with CNBC's Meg Tirrell.

  • This is what's driving biotech   Wednesday, 8 Apr 2015 | 5:30 AM ET
    This is what's driving biotech

    Eric Schmidt, senior research analyst at Cowen & Co, explains why despite the outperformance in the biotech sector, there's more room to run.

  • Halftime's hottest trades today: BTU, FB, JPM & XBI

    Halftime's hottest trades today: 6 trades in 50 seconds. Exploring social media rallies, biotech's reversal, earnings season, Peabody Energy, and JP Morgan.

  • LONDON, April 1- A European project to streamline drug approvals moves up a gear next week when regulators sit down with the first company to have an experimental product assessed under a new flexible pilot scheme. In the United States, the Food and Drug Administration has introduced a successful "breakthrough" designation, which has speeded up approval of...

  • The next buzz in biotech   Tuesday, 31 Mar 2015 | 11:30 AM ET
    The next buzz in biotech

    As gene therapy emerges in the biotech industry and Phil Nadeau, Cowen and Company Biotechnology Analyst, explains why it could be the next billion dollar industry.

  • Genfit sinks 31%, but CEO defends liver drug results Friday, 27 Mar 2015 | 3:30 PM ET
    A researcher works in a laboratory of French biopharmaceutical company Genfit, in Loos, northern France, Nov. 15, 2012.

    The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.

  • Will the biotech run resume?   Friday, 27 Mar 2015 | 12:00 AM ET
    Will the biotech run resume?

    After a tough week for biotech stocks, David Seaburg of Cowen & Co. and Craig Johnson of Piper Jaffray call the next move.

  • Déjà vu for biotechs   Thursday, 26 Mar 2015 | 2:33 PM ET
    Déjà vu for biotechs

    CNBC's Meg Tirrell reports on the recent drop in biotechs and whether it is a threat to the overall market.

  • Be selective in biotech: Pro   Wednesday, 25 Mar 2015 | 3:20 PM ET
    Be selective in biotech: Pro

    CNBC contributor Barbara Ryan of Clermont Partners, discusses whether biotech is a good place to be right now, and how investors

  • JERUSALEM, March 25- Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukaemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its...

  • TEL AVIV/ FRANKFURT, March 12- Two years after scientists cooked up the first test tube beef hamburger, researchers in Israel are working on an even trickier recipe: the world's first lab-grown chicken. Professor Amit Gefen, a bioengineer at Tel Aviv University, has begun a year-long feasibility study into manufacturing chicken in a lab, funded by a non-profit...

  • Biotech brawl: Bull vs. ...bull   Friday, 27 Feb 2015 | 3:16 PM ET
    Biotech brawl: Bull vs. ...bull

    Eric Schmidt, Cowen & Co. biotech analyst, thinks biotech will continue to be a great business and will move higher. Insight, with Geoff Porges, Sanford Bernstein.

  • Feb 20- Europe has approved the Western world's first medicine containing stem cells to treat a rare condition caused by burns to the eye, marking a milestone in the use of the technology. Holoclar, from privately held Italian company Chiesi, was given a marketing green light on Friday by the European Commission for treating so-called limbal stem cell...

  • Who can beat the 'superbug'?   Thursday, 19 Feb 2015 | 5:27 PM ET
    Who can beat the 'superbug'?

    A new antibiotic-resistant "superbug" may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. What companies may be on track to combat the deadly virus, with CNBC's Meg Tirrell.